During 2010, outbreaks of serogroup C meningococcal (MenC) disease occurred in 2 oil refineries in São Paulo State, Brazil, leading to mass vaccination of employees at 1 refinery with a meningococcal polysaccharide A/C vaccine. A cross-sectional study was conducted to assess the prevalence of meningococci carriage among workers at both refineries and to investigate the effect of vaccination on and the risk factors for pharyngeal carriage of meningococci. Among the vaccinated and nonvaccinated workers, rates of overall meningococci carriage (21.4% and 21.6%, respectively) and of MenC carriage (6.3% and 4.9%, respectively) were similar. However, a MenC strain belonging to the sequence type 103 complex predominated and was responsible for the increased incidence of meningococcal disease in Brazil. A low education level was associated with higher risk of meningococci carriage. Polysaccharide vaccination did not affect carriage or interrupt transmission of the epidemic strain. These findings will help inform future vaccination strategies.

In Brazil, meningococcal disease is endemic; 1.5–2.0 cases per 100,000 inhabitants were reported during 2000–2009. Since 2002, a substantial increase has been observed in the proportion of cases attributed to meningococcus serogroup C (MenC) that is associated with the sequence type (ST) 103 complex, and MenC is currently responsible for most cases of meningococcal disease in Brazil (1–3).

Several outbreaks of MenC disease have been reported in Brazil in recent years (2,4–6). To control these outbreaks, chemoprophylaxis is administered to contacts of infected persons, and vaccination is often recommended for persons in age groups at higher risk for infection. In these reactive vaccination campaigns, meningococcal C conjugate (MCC) vaccine use is restricted to children <2 years of age because of cost and supply issues; meningococcal A/C polysaccharide vaccine is recommended for persons ≥2 years of age (1–3).

Published data describing meningococci carriage in Brazil are limited. Few studies have been conducted that assess 1) the role of carriage prevalence in the dynamics of carriage and disease or 2) the potential effect of control programs, such as vaccination, on the transmission of meningococci. Thus, we conducted a cross-sectional study with the primary objective of assessing the prevalence of meningococcal carriage among workers at 2 oil refineries in São Paulo State, Brazil, where outbreaks of MenC disease occurred in 2010. We also investigated the effect of meningococcal A/C polysaccharide vaccination and risk factors on pharyngeal carriage of meningococci.

Methods

During March 29–June 30, 2010, an outbreak of MenC disease, associated with the ST103 complex, occurred in an oil refinery (Refinery A) with 17,590 workers in São Paulo State, Brazil. A total of 18 cases and 3 deaths (case-fatality rate 16.7%) were associated with the outbreak. Six of the cases and 2 deaths involved Refinery A workers, and 12 of the cases and 1 death involved contacts (family members) of the refinery workers. The case-patients were residents of Cosmópolis, a municipality with 59,000 inhabitants located near Refinery A.
On March 29, health authorities were notified of the first 3 case-patients (2 adult workers at Refinery A and an 8-month-old child whose father worked at Refinery A). An investigation was initiated, and chemoprophylaxis with rifampin was recommended for all close contacts of the 3 index case-patients. During the following 2 weeks, 5 new cases of MenC disease were identified (3 in Refinery A workers and 2 in children who were relatives of Refinery A workers). With these new cases, the incidence of meningococcal disease reached 34.1 cases/100,000 persons at Refinery A. Meningococcal A/C polysaccharide vaccination was recommended for all 17,590 workers at Refinery A. Vaccination began on April 16, and 1 week later, 91% coverage of workers at Refinery A was achieved. However, despite the vaccination program, 10 new cases of MenC disease occurred: 9 cases were in family contacts and 1 case was in a Refinery A worker who had received vaccine 1 day before symptom onset.

The incidence of MenC disease in Cosmópolis subsequently reached 20.2 cases/100,000 persons. Cases occurred in relatives (8 months to 16 years of age) of Refinery A workers, prompting a mass vaccination of 18,571 inhabitants of Cosmópolis who were 2 months to 19 years of age. Vaccination began on June 30, and 90.5% coverage was achieved 1 week later. Infants and toddlers received MCC vaccine, and persons 2–19 years of age received meningococcal A/C polysaccharide vaccine. In the months following the vaccination campaign, no more MenC cases were reported, and the outbreak was considered controlled.

The second outbreak of MenC disease occurred in a refinery with 16,000 workers (Refinery B) in São José dos Campos, a city with 610,095 inhabitants in São Paulo State. On July 10, 2010, a worker at Refinery B was reported to have MenC disease, and on July 18, a second worker was reported to be infected. An investigation identified 10 other reported cases in São José dos Campos during April–July, 2010; the 10 cases were in children <4 years of age who were household contacts of Refinery B workers. Of the 12 identified case-patients, 6 died. As in Cosmópolis, these initial cases were considered the index cases. In Refinery B, the incidence of meningococcal disease reached 12.5 cases/100,000 persons, and a decision was made to provide chemoprophylaxis, but not vaccine, to all close contacts of index case-patients. On August 8, 1 new case of meningococcal disease was reported in a family contact of a Refinery B worker; no further cases were reported in 2010.

Beginning in December 2010, we conducted a cross-sectional study of 483 workers (18–39 years of age) from Refinery A, where mass vaccination had been recommended, and Refinery B, where mass vaccination had not been advised. All study participants gave informed consent. A questionnaire was used to obtain information regarding age, sex, recent respiratory tract infections, active and passive smoking, alcohol consumption, recent antimicrobial drug use, length of employment at the refinery, number of household members living in the same room, level of education, and meningococcal A/C polysaccharide vaccination status.

Specimen Collection

During the first 2 weeks of December, 2010, we obtained oropharyngeal swab samples from 483 refinery workers (238 vaccinated workers from Refinery A and 245 nonvaccinated workers from Refinery B). The samples were immediately put into transport medium (7) and, within 4–5 h, sent to the Adolfo Lutz Institute (São Paulo, Brazil), the National Reference Laboratory for Bacterial Meningitis, where they were stored until use. The stored oropharyngeal swabs were plated onto selective medium, and after 24–48 h of incubation at 37°C (±2°C) in 5% CO₂, the samples were inspected. Samples with meningococcal-like colonies were subcultured on blood agar medium for species identification. Isolates identified as Neisseria meningitidis were serogrouped by using an agglutination test. Antisera were obtained for serogroups A, B, C, E, W, X, Y, and Z (8,9).

DNA Extraction and Real-Time PCR

DNA from each sample was extracted and purified by using the QIAamp DNA MiniKit (QIAGEN, Alameda, CA, USA) or a similar testing kit according to the manufacturer’s instructions. Primers and fluorescent probes were used for the detection of N. meningitidis ctra (10) and sodC genes by real-time PCR (11). Samples positive for N. meningitidis were genotyped by using primers and fluorescent probes for N. meningitidis serogroups A, B, C, W, and X.

Serotyping and Multilocus Sequence Typing

Serotyping for all N. meningitidis isolates was performed by dot blot analysis, using whole-cell suspensions as described (12). Multilocus sequence typing was performed according to the methods of Maiden et al. (13). Primers, determination of sequence alleles, and designation of sequence types are described on the Neisseria Multi Locus Sequence Typing website (http://neisseria.org/nm/mlst).

Statistical Analyses

Using an estimate that the prevalence of meningococcal carriage among adults would be ∼18% (±5%), we calculated that ∼225 study participants from each refinery would be needed to analyze all variables. Demographic data for all participants and typing results of N. meningitidis isolates were entered into an EpiInfo database (www.cdc.gov/epiinfo/) and compared by using the 2-sided Fisher exact test. Assessment of risk factors was performed using Fisher exact test.
Results

Of the 483 oropharyngeal samples tested, 104 (21.5%; 95% CI 18.0%–25.5%) were positive for meningococci. Carriage rates were similar among workers from both refineries (21.4% vs. 21.6%). Of the 104 positive samples, 95 were detected by culture and real-time PCR, 1 was detected by culture only, and 8 were detected by real-time PCR only.

The serogroup and genogroup could be determined for 56 of the 104 meningococci-positive samples: 27 (48.2%) were serogroup C, 9 (16.1%) serogroup B, 8 (14.3%) serogroup E, 7 (12.5%) serogroup Y, and 5 (8.9%) serogroup W. The serogroup could not be determined for 48 (46.1%) isolates. The difference in MenC carriage rates among workers at the 2 refineries was not significant: 6.3% at Refinery A and 4.9% at Refinery B (p = 0.48) (Table 1).

Serotyping and Multilocus Sequence Typing

A total of 38 different serotype–serosubtype antigen combinations were identified among the 96 N. meningitidis isolates. Among MenC isolates, phenotype C:23:P.14–6 was the most prevalent (10/13 [77%]). Eleven different STs were found among 27 isolates characterized by multilocus sequence typing. The 11 STs were grouped into 6 different clonal complexes: ST103 complex (n = 7), ST11 complex (n = 5), ST213 complex (n = 1), ST32 complex (n = 3), ST41/44/Lineage 3 (n = 1), ST461 (n = 1). The most prevalent clonal complex, ST103 complex, was represented by ST3780 (n = 6) (Table 2).

We did not find an increased risk of meningococcal carriage associated with any of the potential risk factors studied, except low level of education. A low education level (i.e., not completing secondary education) was significantly associated with a higher risk for carriage of meningococci, regardless of serogroup identification (Table 3).

Conclusions

Most published studies report a consistently low rate (usually <1%) of MenC carriage during outbreaks of MenC disease (14–16). However, after outbreaks at 2 oil refineries in São Paulo State, Brazil, we found high rates (6.3% and 4.9%, respectively) of MenC carriage among refinery workers.

Mass vaccination with a meningococcal A/C polysaccharide vaccine was conducted at Refinery A, and high coverage (91%) was achieved among workers. This intervention controlled the MenC outbreak in the refinery; only 1 new case occurred after the vaccination campaign, but that case cannot be considered the result of a vaccine failure because it occurred <14 days after the refinery worker was vaccinated. These findings likely indicate that the workers received direct protection against MenC from vaccine. However, after the vaccination campaign, 9 new cases of MenC infection occurred in children who were household contacts of vaccinated workers, without any known contact among them.

The prevalence of MenC carriage was high among workers at both refineries, even though 91% of Refinery A workers had received meningococcal A/C polysaccharide vaccine 6 months before our study began. More striking, carriage rates among vaccinated and nonvaccinated workers were similar. These findings suggest that meningococcal A/C polysaccharide vaccine had no effect on MenC carriage. Most of the studies conducted among nonmilitary populations demonstrated that these vaccines cannot significantly reduce meningococcal carriage (17–20). The short-term persistence of circulating antibodies and the quality of the immune response induced after vaccination with a polysaccharide vaccine may partly explain why these vaccines have no effect on carriage (20–24).

In contrast to polysaccharide vaccines, conjugate vaccines lead to the production of very high antibody concentrations, even in infants, and induce immunologic memory with higher antibody avidity and increased serum bactericidal activity, thus providing more robust long-term protection. In addition, conjugate vaccines also prevent the acquisition of carriage among vaccinees and, by interrupting transmission, provide indirect protection to unvaccinated, susceptible persons; this herd immunity proved key to the success of MCC vaccination programs in various countries (25–27).

### Table 1. Pharyngeal carriage of Neisseria meningitidis among vaccinated and nonvaccinated workers at 2 oil refineries, São Paulo, Brazil, 2010*

| N. meningitidis serogroup | Refinery A* | Refinery B† | Total | p value‡ |
|---------------------------|-------------|-------------|-------|---------|
| All                       | 51 (21.4)   | 53 (21.6)   | 104 (21.5) | 1.00    |
| C                         | 15 (6.3)    | 12 (4.9)    | 27 (5.6) | 0.64    |
| W                         | 4 (1.6)     | 5 (2.0)     | 9 (1.9)  | 1.00    |
| Y                         | 4 (1.6)     | 1 (0.4)     | 5 (1.0)  | 0.35    |
| E                         | 5 (2.1)     | 2 (0.8)     | 7 (1.4)  | 0.43    |
| Nongroupable              | 3 (1.2)     | 5 (2.0)     | 8 (1.7)  | 0.76    |
| Negative                  | 187 (78.6)  | 192 (78.4)  | 379 (78.5) |        |
| Total                     | 238 (100.0) | 245 (100.0) | 483 (100.0) |        |

*Vaccinated workers.
†Unvaccinated workers.
‡By Fisher exact test.
The characterization of the \textit{N. meningitidis} strains isolated from the patients (workers and family contacts) during the outbreak in Refinery A has been described (28). The characterization showed that all MenC isolates were genetically related and displayed the same phenotype, C:23:P1.14–6, associated with ST3780 of the ST103 complex. The characterization of the 13 MenC carriage strains recovered from workers at both refineries in our study showed that most (10/13) displayed the C:23:P1.14–6 phenotype. These strains displayed 2 STs: ST3780, which belongs to ST103 complex, and ST8730, assigned without clonal complex. In Brazil, the increase in MenC disease during the last decade has been associated with the emergence of this virulent clone belonging to the ST103 complex (2,29). The ability of MCC vaccines to effect carriage of strains from the ST103 complex has yet to be shown. The recent introduction of MCC vaccine in the routine immunization program in Brazil will provide this opportunity, highlighting the importance of

### Table 2. Phenotypic and genotypic characteristics of \textit{Neisseria meningitidis} strains isolated from nasopharyngeal samples of workers at 2 oil refineries, São Paulo, Brazil, 2010*

| Refinery, \textit{N. meningitidis} serogroup, worker's age, y | Serotype:serosubtype | ST | Clonal complex |
|---------------------------------------------------------------|----------------------|----|----------------|
| A                                                             |                      |    |                |
| 20                                                            | 4,7:NST              | 9858|                |
| 29                                                            | 19,1:P1,14           | 6481| ST213 complex  |
| 29                                                            | 17:P1.1              | 8035| ST41/44 complex/Lineage 3 |
| C                                                             |                      |    |                |
| 26                                                            | 23:P1.14–6           | 3780| ST103 complex  |
| 28                                                            | 23:P1.14–6           | 8730| NA             |
| 21                                                            | 23:P1.14–6           | 8730| NA             |
| 22                                                            | 23:P1.14–6           | 8730| NA             |
| 20                                                            | 23:P1.14–6           | 8730| NA             |
| W                                                             |                      |    |                |
| 21                                                            | 2b:P1.2              | 11  | ST11 complex/ET-37 complex |
| 27                                                            | 2b:P1.5,2            | 11  | ST11 complex/ET-37 complex |
| 24                                                            | 2b:P1.5,2            | 11  | ST11 complex/ET-37 complex |
| Y                                                             |                      |    |                |
| 23                                                            | 2a:P1.5,2            | 11  | ST11 complex/ET-37 complex |
| 26                                                            | 17,7:P1.5            | 6525| NA             |
| 22                                                            | 17,7:P1.5            | 6525| NA             |

### Table 3. Risk factors for pharyngeal carriage of \textit{Neisseria meningitidis} among workers at 2 oil refineries, São Paulo, Brazil, 2010

| Variable                              | All \textit{N. meningitidis} strains | Serogrouped \textit{N. meningitidis} strains |
|---------------------------------------|-------------------------------------|---------------------------------------------|
|                                       | % Workers exposed | % Workers not exposed | p value* | % Workers exposed | % Workers not exposed | p value* |
| Antimicrobial drug use†                | 12.9 | 22.1 | 0.16 | 3.2 | 12.0 | 0.11 |
| Crowded living conditions              | 17.4 | 22.9 | 0.14 | 9.9 | 12.3 | 0.35 |
| Active smoking                         | 23.2 | 21.2 | 0.41 | 11.6 | 11.6 | 0.58 |
| Respiratory symptoms†                  | 24.2 | 20.9 | 0.26 | 10.1 | 11.9 | 0.44 |
| Low level of education‡                | 32.9 | 19.2 | 0.01 | 17.0 | 10.6 | 0.07 |

*NST, not serosubtypeable; ST, sequence type; NA, assigned without clonal complex.

†In the 15 d before the collection of the nasopharyngeal sample.
‡Defined as not completing secondary education.
carefully designed studies to measure the effect of the vaccine on carriage and transmission.

Meningococcal carriage was not associated with any of the risk factors evaluated in our study, except the level of education, which was inversely related to the prevalence of carriage. The higher percentage of MenC carriers among study participants with a lower level of education presumably reflects associated socioeconomic conditions and social behaviors. Less-educated workers in oil refinery settings are also more likely to perform activities that require the use of ear devices as protection from the loud environment. The wearing of such devices forces workers to stay very close to each other to facilitate conversation among them, and such close working situations also facilitate transmission of meningococci.

Although the relationship between meningococcal carriage prevalence and disease incidence is not fully understood, the evidence gathered during this study showed a dominance of the C:23:P1.14–6 phenotype strain among workers from both refineries, reinforcing the concept that the dominance of a particular strain is an important marker of epidemic conditions (30,31). Also, in accordance with previous findings from other studies, we observed that polysaccharide vaccination had no effect on carriage and did not interrupt transmission to susceptible contacts (4,24). These results represent a challenge to the current policy of using the meningococcal polysaccharide A/C vaccine to control outbreaks of MenC disease, and they have key implications for future vaccination strategies. Our findings emphasize the need to review such policies and to consider using MCC vaccines rather than meningococcal polysaccharide A/C vaccines to control MenC disease outbreaks.

Acknowledgments
We thank Marcelle Vigos dos Santos, Conceição Zanelato, Maria Vaneide de Paiva, and Martha Galhardo for assistance in conducting microbiological tests.

An unrestricted education grant from Sanofi Pasteur vaccines was provided for this study.

M.A.P.S. has been a scientific consultant and a speaker for GlaxoSmithKline, Novartis, Wyeth/Pfizer, Sanofi Pasteur, and MSD (MerekSharpDohme); J.C.M. has been a scientific consultant for Novartis, Wyeth/Pfizer, and Sanofi Pasteur. M.C.C.B. has been a speaker for Sanofi-Pasteur, Pfizer, and Glaxo Smith Kline. A.P.L. has been a speaker for Novartis and Sanofi Pasteur. M.C.O.G. has been a speaker for Novartis.

Dr Sáfadi is a pediatric infectious disease specialist and an assistant professor in the Department of Pediatrics at Faculdade de Ciências Médicas da Santa Casa, São Paulo. His primary research interests include epidemiology and prevention of childhood infectious diseases.

References
1. Brazilian Ministry of Health. Health surveillance [cited 2012 Aug 20]. http://portal.saude.gov.br/portal/saude/area.cfm?id_area=962.
2. Sáfadi MA, Gonzalez-Ayala S, Jäkel A, Wieffer H, Moreno C, Vyse A. The epidemiology of meningococcal disease in Latin America 1945–2010: an unpredictable and changing landscape. Epidemiol Infect. 2013;141:447–58. http://dx.doi.org/10.1017/S0950268812001689
3. Centro de Vigilância Epidemiológica. “Prof. Alexandre Vranjac” (Epidemiologic Surveillance Center), Brazil. Respiratory transmitted diseases [in Portuguese] [cited 2012 Aug 30]. http://www.cve.saude.sp.gov.br/htm/resp/dm_soro.htm
4. Iser BPM, Lima CAV, de Moraes C, de Almeida RP, Watanabe LT, Alves SL, et al. Outbreak of Neisseria meningitidis C in workers at a large food-processing plant in Brazil: challenges of controlling disease spread to the larger community. Epidemiol Infect. 2012;140:906–15. http://dx.doi.org/10.1017/S095026881001610
5. Gorla MC, de Lemos AP, Quaresma M, Vilasboas R, Marques O, de Sá MU, et al. Phenotypic and molecular characterization of serogroup C Neisseria meningitidis associated with an outbreak in Bahia, Brazil. Enferm Infec Microbiol Clin. 2012;30:56–9. http://dx.doi.org/10.1016/j.eimc.2011.07.022
6. Puricelli RCB, Kupek E, Bertoncini RCC. Control of a community outbreak of group C meningococcal meningitis in Corupa, Santa Catarina State, Brazil, based on a rapid and effective epidemiological surveillance and immunization [in Portuguese]. Cad Saude Publica. 2004;20:959–67 http://dx.doi.org/10.1590/S0102-311X2004000400010
7. O’Brien KL, Brandson MA, Dagan R, Yagupsky P, Jancio J, Elliott J, et al. Evaluation of a medium (STGG) for transport and optimal recovery of Streptococcus pneumoniae from nasopharyngeal secretions collected during field studies. J Clin Microbiol. 2001;39:1021–4. http://dx.doi.org/10.1128/JCM.39.3.1021-1024.2001
8. World Health Organization Communicable Disease Surveillance and Response. Laboratory methods for the diagnosis of meningitis caused by Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. WHO/CDS/CSR/EDC/99.7; 1998 [cited 2012 Nov 7]. http://www.who.int/csr/resources/publications/ meningitis/worldcstatesdrec997.pdf
9. Alkmin MG, Shimizu SH, Landgraf IM, Gaspari EN, Melles CE. Production and immunochemical characterization of Neisseria meningitidis group B antisem for the diagnosis of purulent meningitis. Braz J Med Biol Res. 1994;27:1627–34.
10. Mothershed EA, Sacchi CT, Whitney AM, Barnett GA, Ajello GW, Schmink S. Use of real-time PCR to resolve slide agglutination discrepancies in serogroup identification of Neisseria meningitidis. J Clin Microbiol. 2004;42:320–8. http://dx.doi.org/10.1128/JCM.42.1.320-328.2004
11. Dolan Thomas J, Hatcher CP, Satterfield DA, Theodore MJ, Bach MC, Linscott KB, et al. sO1C-based real-time PCR for detection of Neisseria meningitidis. PLoS ONE. 2011;6:e19361. http://dx.doi.org/10.1371/journal.pone.0019361
12. Wedege E, Hobly EA, Rosenqvist E, Froholm LO. Serotyping and subtyping of Neisseria meningitidis isolates by co-agglutination, dot-blotting and ELISA. J Med Microbiol. 1990;31:195–201. http://dx.doi.org/10.1099/00222615-31-3-195
13. Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, Zhang Q, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A. 1998;95:3140–5. http://dx.doi.org/10.1073/pnas.95.6.3140
14. Jones GR, Williams JN, Christodoulides M, Jolley K, Heckels JE. Lack of immunity in university students before an outbreak of serogroup C meningococcal infection. J Infect Dis. 2000;181:1172–5. http://dx.doi.org/10.1086/315352

RESEARCH

810 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 20, No. 5, May 2014
15. Conyn-van Spaendonck MA, Reintjes R, Spanjaard L, van Kregten E, Kraaijeveld AG, Jacobs PH. Meningococcal carriage in relation to an outbreak of invasive disease due to Neisseria meningitidis serogroup C in the Netherlands. J Infect. 1999;39:42–8. http://dx.doi.org/10.1016/S0163-4453(99)90101-9

16. Patrick DM, Champagne S, Goh SH, Arsenault G, Thomas E, Shaw C, et al. Neisseria meningitidis carriage during an outbreak of serogroup C disease. Clin Infect Dis. 2003;37:1183–8. http://dx.doi.org/10.1086/378743

17. Ramos Aceitero JM. Surveys on the rates of healthy carriers of Neisseria meningitidis and characterization of circulating strains. Rev Esp Salud Publica. 2000;74:413–7.

18. Cardeñosa N, Domínguez A, Orcau A, Pañella H, Godoy P, Minguell S, et al. Carriers of Neisseria meningitidis in household contacts of meningococcal disease cases in Catalonia (Spain). Eur J Epidemiol. 2001;17:877–84. http://dx.doi.org/10.1023/A:1015696513062

19. Domínguez A, Cardeñosa N, Izquierdo C, Sánchez F, Margall N, Vazquez JA, et al. Prevalence of Neisseria meningitidis carriers in the school population of Catalonia, Spain. Epidemiol Infect. 2001;127:425–33. http://dx.doi.org/10.1017/S0950268801006173

20. Poland GA. Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines. Clin Infect Dis. 2010;50(Suppl 2):S45–53. http://dx.doi.org/10.1086/648964

21. Granoff DM, Harrison LH, Borrow R. Meningococcal vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 5th ed. London: Saunders-Elsevier; 2008. p. 399–434.

22. Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev. 2007;31:1–14 http://dx.doi.org/10.1111/j.1574-6976.2006.00051.x

23. Danzig L. Meningococcal vaccines. Pediatr Infect Dis J. 2004;23 (Suppl):S285–92.

24. Granoff DM, Pollard AJ. Reconsideration of the use of meningococcal polysaccharide vaccine. Pediatr Infect Dis J. 2007;26:716–22. http://dx.doi.org/10.1097/INF.0b013e3180c2e25

25. Maiden MC, Ibarz-Pavón AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197:737–43. http://dx.doi.org/10.1086/527401

26. Sáfadi MA, McIntosh ED. Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies. Expert Rev Vaccines. 2011;10:1717–30. http://dx.doi.org/10.1586/erv.11.159

27. Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines. 2009;8:851–61. http://dx.doi.org/10.1586/erv.09.48

28. Liphaus BL, Cappeletti-Gonçalves-Okai ML, Silva-Delemos AP, Gorla MC, Rodriguez-Fernandes M, Paccola MR, et al. Outbreak of Neisseria meningitidis C in a Brazilian oil refinery involving an adjacent community. Enferm Infec Microbiol Clin. 2013;31:88–92. http://dx.doi.org/10.1016/j.eimc.2012.05.009.

29. de Lemos AP, Yara TY, Gorla MC, de Paiva MV, de Souza AL, Gonçalves MIC, et al. Clonal distribution of invasive Neisseria meningitidis serogroup C strains circulating from 1976 to 2005 in greater São Paulo, Brazil. J Clin Microbiol. 2007;45:1266–73. http://dx.doi.org/10.1128/JCM.02510-06

30. Trotter CL, Greenwood BM. Meningococcal carriage in the African meningitis belt. Lancet Infect Dis. 2007;7:797–803. http://dx.doi.org/10.1016/S1473-3099(07)70288-8

31. Raghunathan PL, Jones JD, Tiendrebéogo SR, Sanou I, Sangaré L, Kouanda S, et al. Predictors of immunity after a major serogroup W-135 meningococcal disease epidemic, Burkina Faso, 2002. J Infect Dis. 2006;193:607–16. http://dx.doi.org/10.1086/499822

Address for correspondence: Marco A. P. Sáfadi, Faculdade de Ciências Médicas da Santa Casa, Alameda dos Indígenas, 228 ZIP 04059-060, São Paulo, Brazil; email: masafadi@uol.com.br